Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 2/2018

01-04-2018 | Review

Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases

Authors: Giovanni B. Gaeta, Massimo Puoti, Nicola Coppola, Teresa Santantonio, Raffaele Bruno, Antonio Chirianni, Massimo Galli

Published in: Infection | Issue 2/2018

Login to get access

Abstract

Aim

This paper is aimed at providing practical recommendations for the management of acute hepatitis C (AHC).

Methods

This is an expert position paper based on the literature revision. Final recommendations were graded by level of evidence and strength of the recommendations.

Results

Treatment of AHC with direct-acting antivirals (DAA) is safe and effective; it overcomes the limitations of INF-based treatments.

Conclusions

Early treatment with DAA should be offered when available.
Literature
1.
Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49:625–33.CrossRefPubMed
2.
3.
Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. Arch Intern Med. 2011;171:242–8.CrossRefPubMed
4.
Spada E, Mele A, Mariano A, Zuccaro O, Tosti ME. SEIEVA collaborating group. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: results from the national surveillance system. J Med Virol. 2013;85:433–40.CrossRefPubMed
5.
Santantonio T, Medda E, Ferrari C, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006;43:1154–9.CrossRefPubMed
6.
Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59:1411–9.CrossRefPubMed
7.
Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr. 2013;163:1549–52.CrossRefPubMed
8.
van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196:230–8.CrossRefPubMed
9.
Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, van der Meer JT, Schinkel J. MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study group. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS. 2011;3(25):F21–7.CrossRef
10.
Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis. 2012;15(55):1408–16.CrossRef
11.
McFaul K, Maghlaoui A, Nzuruba M, et al. Acute hepatitis C infection in HIV-negative men who have sex with men. J Viral Hepat. 2015;22:535–8.CrossRefPubMed
12.
Vanhommerig JW, Lambers FA, Schinkel J, et al. Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study. Open Forum Infect Dis. 2015;2:ofv115.CrossRefPubMedPubMedCentral
13.
Martin TC, Martin NK, Hickman M, et al. HCV reinfection incidence and treatment outcome among HIV-positive MSM in London. AIDS. 2013;27:2551–7.CrossRefPubMed
14.
15.
Ingiliz P, Martin TC, Rodger A, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol. 2017;66:282–7.CrossRefPubMed
16.
Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH. A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users. Hepatology. 2013;57:944–52.CrossRefPubMedPubMedCentral
17.
Pawlotsky JM, Aghemo A, Back D, et al. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.CrossRef
18.
19.
Deterding K, Grüner N, Buggisch P, et al. Hep-Net Acute HCV-III Study Group. Delayed versus immediate treatment for patients with acute hepatitis C: a randomized controlled non-inferiority trial. Lancet Infect Dis. 2013;13:497–506.CrossRefPubMed
20.
Santantonio T, Fasano M, Sagnelli E, et al. Acute hepatitis C: a 24 week course of Peg-interferon a-2b versus a 12 week-course of Peginterferon a-2b alone or with ribavirin. Hepatology. 2014;59:2101–9.CrossRefPubMed
21.
Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43:923–31.CrossRefPubMed
22.
Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632–8.CrossRefPubMed
23.
Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon a therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004;39:1721–31.CrossRefPubMed
24.
Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterolgy. 2010;139:1586–92.CrossRef
25.
Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther. 2006;11:1097–101.PubMed
26.
Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20:1157–61.CrossRefPubMed
27.
Matthews GV, Hellard M, Haber P, et al. Australian Trial in Acute Hepatitis C Study Group. Characteristics and treatment outcomes among HIVinfected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48:650–8.CrossRefPubMedPubMedCentral
28.
Piroth L, Larsen C, Binquet C, Steering Committee of the HEPAIG Study, et al. Treatment of acute hepatitis C in human immunodeficiency virus infected patients: the HEPAIG study. Hepatology. 2010;52:1915–21.CrossRefPubMed
29.
Dore GJ, Hellard M, Matthews GV, et al. Australian Trial In Acute Hepatitis C Study Group. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010;138(1):123–35.CrossRefPubMed
30.
Lambers FA, Brinkman K, Schinkel J, et al. MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study group. Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS. 2011;25(10):1333–6.CrossRefPubMed
31.
Grebely J, Hellard M, Applegate T, ATAHC Study Group, et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS. 2012;26:1653–61.CrossRefPubMedPubMedCentral
32.
Fierer DS, Dieterich DT, Mullen MP, et al. New York Acute Hepatitis C Surveillance Network. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58:873–9.CrossRefPubMed
33.
Boesecke C, van Assen S, Stellbrink HJ, et al. Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection. J Viral Hepat. 2014;21(11):780–5.CrossRefPubMed
34.
Liu CH, Sheng WH, Sun HY, et al. Peginterferon plus ribavirin for HIV-infected patients with treatment-naïve acute or chronic HCV infection in Taiwan: a Prospective Cohort Study. Sci Rep. 2015;30(5):17410.CrossRef
35.
Doyle JS, Deterding K, Grebely J, et al. InC3 Study Group. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat. 2015;22(12):1020–32.CrossRefPubMedPubMedCentral
36.
Boesecke C, Ingiliz P, Reiberger T, NEAT Study Group, et al. Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. Infection. 2016;44(1):93–101.CrossRefPubMed
37.
Zhang B, Nguyen NH, Yee BE, et al. Treatment of acute hepatitis C infection with pegylated interferon and ribavirin in patients coinfected with human immunodeficiency virus: a systematic review and meta-analysis. Intervirology. 2015;58:242–9.CrossRefPubMed
38.
39.
Fabrizi F, Dixit V, Messa P, et al. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis. J Viral Hepat. 2012;19:784–9.CrossRefPubMed
40.
Fierer D, El Sayed A,Palaniswami P. Sofosbuvir/Ledipasvir in the Treatment of Early (“acute”) HCV Infection in HIV-infected Men. EASL Meeting 2017, Amsterdam; Abs THU-250.
41.
Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): anopen-label, single-arm, phase 2 study. Lancet Infect Dis. 2017;17:215–22.CrossRefPubMed
42.
Basu P, Shah NJ, John N, Aloysius M, Brown R. Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. SLAM C study. Interim data. AASLD Meeting 2015, San Francisco, November 13–17; Abstract 1074.
43.
Rockstroh JK, Bhagani S, Hyland RH, et al. Ledipasvir/Sofosbuvir for 6 Weeks to treat acute hepatitis C genotype 1 or 4 infection in patients with HIV coinfecion: an open label, single-arm trial. Lancet Gastroent. 2017;2:347–53.CrossRef
44.
Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1 infected individuals:SWIFT-C. Clin Infect Dis. 2017;63:528–31.
45.
Fierer DS, Barbati Z, Dieterich D, et al. Sofosbuvir in the Treatment of Acute HCV Infection in HIV-infected Men. AASLD Liver Meeting 2015, San Francisco, November 13–17; Abstract 1090.
46.
Martinello M, Gane E, Hellard M, et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE-C II study. Hepatology. 2016;64:1911–21.CrossRefPubMed
47.
48.
Abravanel F, Métivier S, Chauveau M, Péron JM, Izopet J. Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men. Clin Infect Dis. 2016;63:1271–2.PubMed
Metadata
Title
Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases
Authors
Giovanni B. Gaeta
Massimo Puoti
Nicola Coppola
Teresa Santantonio
Raffaele Bruno
Antonio Chirianni
Massimo Galli
Publication date
01-04-2018
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 2/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-017-1107-z

Other articles of this Issue 2/2018

Infection 2/2018 Go to the issue

Case Report

Kocuria massiliensis sp. nov, a new bacterial species isolated from a patient with foot osteomyelitis

Case Report

Neisseria cinerea bacteremia in a patient receiving eculizumab: a case report

Brief Report

Antifungal activity of Myrtus communis against Malassezia sp. isolated from the skin of patients with pityriasis versicolor

Original Paper

The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011–2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group

Original Paper

Alveolar echinococcosis in Germany, 1992–2016. An update based on the newly established national AE database

Original Paper

Influence of a strictly perioperative antibiotic prophylaxis vs a prolonged postoperative prophylaxis on surgical site infections in maxillofacial surgery
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits